2006-08-01
AUTHORSNaoto Tomita, Fumio Kodama, Heiwa Kanamori, Shigeki Motomura, Yoshiaki Ishigatsubo
ABSTRACTThis review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin’s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma. More... »
PAGES128-135
http://scigraph.springernature.com/pub.10.1532/ijh97.06091
DOIhttp://dx.doi.org/10.1532/ijh97.06091
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1020980818
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16926134
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Murine-Derived",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antimetabolites, Antineoplastic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Central Nervous System Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cytarabine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lymphoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recurrence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Rituximab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stem Cell Transplantation",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.413045.7",
"name": [
"Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Tomita",
"givenName": "Naoto",
"id": "sg:person.01155656464.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Kodama",
"givenName": "Fumio",
"id": "sg:person.01176656731.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176656731.40"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Kanamori",
"givenName": "Heiwa",
"id": "sg:person.01060176576.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Motomura",
"givenName": "Shigeki",
"id": "sg:person.0727433761.60",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727433761.60"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Ishigatsubo",
"givenName": "Yoshiaki",
"id": "sg:person.01125133646.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.leu.2402573",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053568598",
"https://doi.org/10.1038/sj.leu.2402573"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-003-0737-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051485520",
"https://doi.org/10.1007/s00280-003-0737-2"
],
"type": "CreativeWork"
}
],
"datePublished": "2006-08-01",
"datePublishedReg": "2006-08-01",
"description": "This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin\u2019s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma.",
"genre": "article",
"id": "sg:pub.10.1532/ijh97.06091",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "84"
}
],
"keywords": [
"secondary central nervous system lymphoma",
"central nervous system lymphoma",
"nervous system lymphoma",
"CNS prophylaxis",
"CNS involvement",
"systemic lymphoma",
"system lymphoma",
"risk factors",
"age-adjusted International Prognostic Index score",
"elevated serum lactate dehydrogenase level",
"serum lactate dehydrogenase level",
"International Prognostic Index score",
"Prognostic Index score",
"initiation of treatment",
"reports of patients",
"lactate dehydrogenase levels",
"important risk factor",
"flow cytometry assay",
"intrathecal administration",
"liposomal cytarabine",
"CNS recurrence",
"aggressive NHL",
"extranodal sites",
"histologic evidence",
"histologic subtype",
"cell transplantation",
"Hodgkin's lymphoma",
"polymerase chain reaction",
"dehydrogenase levels",
"anatomic sites",
"correct diagnosis",
"cerebrospinal fluid",
"prophylaxis",
"lymphoma",
"advanced stage",
"index score",
"conventional treatment",
"indicator of risk",
"cytometry assays",
"clinical use",
"chain reaction",
"treatment",
"involvement",
"current knowledge",
"rituximab",
"patients",
"transplantation",
"cytarabine",
"prognosis",
"recurrence",
"NHL",
"main target",
"subtypes",
"incidence",
"diagnosis",
"administration",
"prevention",
"adults",
"factors",
"scores",
"risk",
"testis",
"presentation",
"aggressiveness",
"report",
"status",
"assays",
"recent improvements",
"review",
"initiation",
"evidence",
"target",
"levels",
"sites",
"improvement",
"fluid",
"use",
"stage",
"indicators",
"addition",
"strategies",
"knowledge",
"values",
"reaction",
"approach"
],
"name": "Secondary Central Nervous System Lymphoma",
"pagination": "128-135",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1020980818"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1532/ijh97.06091"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16926134"
]
}
],
"sameAs": [
"https://doi.org/10.1532/ijh97.06091",
"https://app.dimensions.ai/details/publication/pub.1020980818"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:23",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_412.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1532/ijh97.06091"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'
This table displays all metadata directly associated to this object as RDF triples.
241 TRIPLES
22 PREDICATES
126 URIs
116 LITERALS
20 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1532/ijh97.06091 | schema:about | N004b0a428c2e4346a0ce15f220ea8b07 |
2 | ″ | ″ | N03afc7ec2a4843ff83d63d68e3cd7bd7 |
3 | ″ | ″ | N4a1df607a4104c79856edcff524e64ab |
4 | ″ | ″ | N508cc31986384cc998f4b0372c62f7ca |
5 | ″ | ″ | N604605381c0c48779996548bac6cb287 |
6 | ″ | ″ | N7a089e9d6a7745f6b9eebcd127e009ba |
7 | ″ | ″ | Nb6b91978e93e475c892067146bbab2f2 |
8 | ″ | ″ | Nbac9fbc8a9054582984f8236fc363e07 |
9 | ″ | ″ | Nbadfa90f03ae45f89c9d4e30db7d654b |
10 | ″ | ″ | Ne25db49ed1504055b303aa80a6571ff0 |
11 | ″ | ″ | Ne57316f2b3334a8581cd09bb371f1a45 |
12 | ″ | ″ | Ne590d65bf4124821a064514cdf297019 |
13 | ″ | ″ | Nfc7ded9af35043088d5fed62fbee3ae0 |
14 | ″ | ″ | anzsrc-for:11 |
15 | ″ | ″ | anzsrc-for:1112 |
16 | ″ | schema:author | N1a29dd69908a47d89098ea1e58c04262 |
17 | ″ | schema:citation | sg:pub.10.1007/s00280-003-0737-2 |
18 | ″ | ″ | sg:pub.10.1038/sj.leu.2402573 |
19 | ″ | schema:datePublished | 2006-08-01 |
20 | ″ | schema:datePublishedReg | 2006-08-01 |
21 | ″ | schema:description | This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin’s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma. |
22 | ″ | schema:genre | article |
23 | ″ | schema:inLanguage | en |
24 | ″ | schema:isAccessibleForFree | false |
25 | ″ | schema:isPartOf | Nc11670e0948b4495acddacb6bafd2149 |
26 | ″ | ″ | Nea21d583a3db477bb7f807ad22a4135b |
27 | ″ | ″ | sg:journal.1076985 |
28 | ″ | schema:keywords | CNS involvement |
29 | ″ | ″ | CNS prophylaxis |
30 | ″ | ″ | CNS recurrence |
31 | ″ | ″ | Hodgkin's lymphoma |
32 | ″ | ″ | International Prognostic Index score |
33 | ″ | ″ | NHL |
34 | ″ | ″ | Prognostic Index score |
35 | ″ | ″ | addition |
36 | ″ | ″ | administration |
37 | ″ | ″ | adults |
38 | ″ | ″ | advanced stage |
39 | ″ | ″ | age-adjusted International Prognostic Index score |
40 | ″ | ″ | aggressive NHL |
41 | ″ | ″ | aggressiveness |
42 | ″ | ″ | anatomic sites |
43 | ″ | ″ | approach |
44 | ″ | ″ | assays |
45 | ″ | ″ | cell transplantation |
46 | ″ | ″ | central nervous system lymphoma |
47 | ″ | ″ | cerebrospinal fluid |
48 | ″ | ″ | chain reaction |
49 | ″ | ″ | clinical use |
50 | ″ | ″ | conventional treatment |
51 | ″ | ″ | correct diagnosis |
52 | ″ | ″ | current knowledge |
53 | ″ | ″ | cytarabine |
54 | ″ | ″ | cytometry assays |
55 | ″ | ″ | dehydrogenase levels |
56 | ″ | ″ | diagnosis |
57 | ″ | ″ | elevated serum lactate dehydrogenase level |
58 | ″ | ″ | evidence |
59 | ″ | ″ | extranodal sites |
60 | ″ | ″ | factors |
61 | ″ | ″ | flow cytometry assay |
62 | ″ | ″ | fluid |
63 | ″ | ″ | histologic evidence |
64 | ″ | ″ | histologic subtype |
65 | ″ | ″ | important risk factor |
66 | ″ | ″ | improvement |
67 | ″ | ″ | incidence |
68 | ″ | ″ | index score |
69 | ″ | ″ | indicator of risk |
70 | ″ | ″ | indicators |
71 | ″ | ″ | initiation |
72 | ″ | ″ | initiation of treatment |
73 | ″ | ″ | intrathecal administration |
74 | ″ | ″ | involvement |
75 | ″ | ″ | knowledge |
76 | ″ | ″ | lactate dehydrogenase levels |
77 | ″ | ″ | levels |
78 | ″ | ″ | liposomal cytarabine |
79 | ″ | ″ | lymphoma |
80 | ″ | ″ | main target |
81 | ″ | ″ | nervous system lymphoma |
82 | ″ | ″ | patients |
83 | ″ | ″ | polymerase chain reaction |
84 | ″ | ″ | presentation |
85 | ″ | ″ | prevention |
86 | ″ | ″ | prognosis |
87 | ″ | ″ | prophylaxis |
88 | ″ | ″ | reaction |
89 | ″ | ″ | recent improvements |
90 | ″ | ″ | recurrence |
91 | ″ | ″ | report |
92 | ″ | ″ | reports of patients |
93 | ″ | ″ | review |
94 | ″ | ″ | risk |
95 | ″ | ″ | risk factors |
96 | ″ | ″ | rituximab |
97 | ″ | ″ | scores |
98 | ″ | ″ | secondary central nervous system lymphoma |
99 | ″ | ″ | serum lactate dehydrogenase level |
100 | ″ | ″ | sites |
101 | ″ | ″ | stage |
102 | ″ | ″ | status |
103 | ″ | ″ | strategies |
104 | ″ | ″ | subtypes |
105 | ″ | ″ | system lymphoma |
106 | ″ | ″ | systemic lymphoma |
107 | ″ | ″ | target |
108 | ″ | ″ | testis |
109 | ″ | ″ | transplantation |
110 | ″ | ″ | treatment |
111 | ″ | ″ | use |
112 | ″ | ″ | values |
113 | ″ | schema:name | Secondary Central Nervous System Lymphoma |
114 | ″ | schema:pagination | 128-135 |
115 | ″ | schema:productId | N3bf4636cc059447e94bf94bceaecd864 |
116 | ″ | ″ | N5b09797b3c744e728437812d2cb4989a |
117 | ″ | ″ | Na36dba42672f492b93d3cae203573b5b |
118 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1020980818 |
119 | ″ | ″ | https://doi.org/10.1532/ijh97.06091 |
120 | ″ | schema:sdDatePublished | 2022-05-20T07:23 |
121 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
122 | ″ | schema:sdPublisher | Nc74e87eaf0234f44bd3fad53c8439e61 |
123 | ″ | schema:url | https://doi.org/10.1532/ijh97.06091 |
124 | ″ | sgo:license | sg:explorer/license/ |
125 | ″ | sgo:sdDataset | articles |
126 | ″ | rdf:type | schema:ScholarlyArticle |
127 | N004b0a428c2e4346a0ce15f220ea8b07 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
128 | ″ | schema:name | Lymphoma |
129 | ″ | rdf:type | schema:DefinedTerm |
130 | N03afc7ec2a4843ff83d63d68e3cd7bd7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
131 | ″ | schema:name | Rituximab |
132 | ″ | rdf:type | schema:DefinedTerm |
133 | N1167130c68aa417980a3affb3f4f4535 | rdf:first | sg:person.0727433761.60 |
134 | ″ | rdf:rest | N1cc0216236334d5f910d26ea3952cc0b |
135 | N1a29dd69908a47d89098ea1e58c04262 | rdf:first | sg:person.01155656464.01 |
136 | ″ | rdf:rest | N3689f7b9d47e4137928600030add838b |
137 | N1cc0216236334d5f910d26ea3952cc0b | rdf:first | sg:person.01125133646.44 |
138 | ″ | rdf:rest | rdf:nil |
139 | N2d81a525fca442e2bb31932e98673ad3 | rdf:first | sg:person.01060176576.11 |
140 | ″ | rdf:rest | N1167130c68aa417980a3affb3f4f4535 |
141 | N3689f7b9d47e4137928600030add838b | rdf:first | sg:person.01176656731.40 |
142 | ″ | rdf:rest | N2d81a525fca442e2bb31932e98673ad3 |
143 | N3bf4636cc059447e94bf94bceaecd864 | schema:name | pubmed_id |
144 | ″ | schema:value | 16926134 |
145 | ″ | rdf:type | schema:PropertyValue |
146 | N4a1df607a4104c79856edcff524e64ab | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
147 | ″ | schema:name | Antibodies, Monoclonal |
148 | ″ | rdf:type | schema:DefinedTerm |
149 | N508cc31986384cc998f4b0372c62f7ca | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
150 | ″ | schema:name | Adult |
151 | ″ | rdf:type | schema:DefinedTerm |
152 | N5b09797b3c744e728437812d2cb4989a | schema:name | doi |
153 | ″ | schema:value | 10.1532/ijh97.06091 |
154 | ″ | rdf:type | schema:PropertyValue |
155 | N604605381c0c48779996548bac6cb287 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
156 | ″ | schema:name | Stem Cell Transplantation |
157 | ″ | rdf:type | schema:DefinedTerm |
158 | N7a089e9d6a7745f6b9eebcd127e009ba | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
159 | ″ | schema:name | Cytarabine |
160 | ″ | rdf:type | schema:DefinedTerm |
161 | Na36dba42672f492b93d3cae203573b5b | schema:name | dimensions_id |
162 | ″ | schema:value | pub.1020980818 |
163 | ″ | rdf:type | schema:PropertyValue |
164 | Nb6b91978e93e475c892067146bbab2f2 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
165 | ″ | schema:name | Male |
166 | ″ | rdf:type | schema:DefinedTerm |
167 | Nbac9fbc8a9054582984f8236fc363e07 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
168 | ″ | schema:name | Recurrence |
169 | ″ | rdf:type | schema:DefinedTerm |
170 | Nbadfa90f03ae45f89c9d4e30db7d654b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
171 | ″ | schema:name | Humans |
172 | ″ | rdf:type | schema:DefinedTerm |
173 | Nc11670e0948b4495acddacb6bafd2149 | schema:issueNumber | 2 |
174 | ″ | rdf:type | schema:PublicationIssue |
175 | Nc74e87eaf0234f44bd3fad53c8439e61 | schema:name | Springer Nature - SN SciGraph project |
176 | ″ | rdf:type | schema:Organization |
177 | Ne25db49ed1504055b303aa80a6571ff0 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
178 | ″ | schema:name | Antimetabolites, Antineoplastic |
179 | ″ | rdf:type | schema:DefinedTerm |
180 | Ne57316f2b3334a8581cd09bb371f1a45 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
181 | ″ | schema:name | Female |
182 | ″ | rdf:type | schema:DefinedTerm |
183 | Ne590d65bf4124821a064514cdf297019 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
184 | ″ | schema:name | Central Nervous System Neoplasms |
185 | ″ | rdf:type | schema:DefinedTerm |
186 | Nea21d583a3db477bb7f807ad22a4135b | schema:volumeNumber | 84 |
187 | ″ | rdf:type | schema:PublicationVolume |
188 | Nfc7ded9af35043088d5fed62fbee3ae0 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
189 | ″ | schema:name | Antibodies, Monoclonal, Murine-Derived |
190 | ″ | rdf:type | schema:DefinedTerm |
191 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
192 | ″ | schema:name | Medical and Health Sciences |
193 | ″ | rdf:type | schema:DefinedTerm |
194 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
195 | ″ | schema:name | Oncology and Carcinogenesis |
196 | ″ | rdf:type | schema:DefinedTerm |
197 | sg:journal.1076985 | schema:issn | 0925-5710 |
198 | ″ | ″ | 1865-3774 |
199 | ″ | schema:name | International Journal of Hematology |
200 | ″ | schema:publisher | Springer Nature |
201 | ″ | rdf:type | schema:Periodical |
202 | sg:person.01060176576.11 | schema:affiliation | grid-institutes:grid.268441.d |
203 | ″ | schema:familyName | Kanamori |
204 | ″ | schema:givenName | Heiwa |
205 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11 |
206 | ″ | rdf:type | schema:Person |
207 | sg:person.01125133646.44 | schema:affiliation | grid-institutes:grid.268441.d |
208 | ″ | schema:familyName | Ishigatsubo |
209 | ″ | schema:givenName | Yoshiaki |
210 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44 |
211 | ″ | rdf:type | schema:Person |
212 | sg:person.01155656464.01 | schema:affiliation | grid-institutes:grid.413045.7 |
213 | ″ | schema:familyName | Tomita |
214 | ″ | schema:givenName | Naoto |
215 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01 |
216 | ″ | rdf:type | schema:Person |
217 | sg:person.01176656731.40 | schema:affiliation | grid-institutes:None |
218 | ″ | schema:familyName | Kodama |
219 | ″ | schema:givenName | Fumio |
220 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176656731.40 |
221 | ″ | rdf:type | schema:Person |
222 | sg:person.0727433761.60 | schema:affiliation | grid-institutes:None |
223 | ″ | schema:familyName | Motomura |
224 | ″ | schema:givenName | Shigeki |
225 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727433761.60 |
226 | ″ | rdf:type | schema:Person |
227 | sg:pub.10.1007/s00280-003-0737-2 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1051485520 |
228 | ″ | ″ | https://doi.org/10.1007/s00280-003-0737-2 |
229 | ″ | rdf:type | schema:CreativeWork |
230 | sg:pub.10.1038/sj.leu.2402573 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1053568598 |
231 | ″ | ″ | https://doi.org/10.1038/sj.leu.2402573 |
232 | ″ | rdf:type | schema:CreativeWork |
233 | grid-institutes:None | schema:alternateName | Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan |
234 | ″ | schema:name | Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan |
235 | ″ | rdf:type | schema:Organization |
236 | grid-institutes:grid.268441.d | schema:alternateName | Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan |
237 | ″ | schema:name | Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan |
238 | ″ | rdf:type | schema:Organization |
239 | grid-institutes:grid.413045.7 | schema:alternateName | Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan |
240 | ″ | schema:name | Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan |
241 | ″ | rdf:type | schema:Organization |